Ceapro Announces Data from Research Collaboration with the
– Oral presentation to highlight unique results from pre-clinical studies characterizing the in vivo bioactivity of
Globe Newswire8-03-2023, 20:50
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26